Form 4/A for CRL Charles River Laboratories
Accepted 2024-01-31 00:00:00 ET · period of report 2024-01-10 · accession 0001127602-24-002811 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2024-01-31 | 2024-01-10 | CRL | Girshick Birgit | COO, Corp. Executive VP | F - Tax | $213.14 | -4,617 | 45.7K | -9% | -$984.1K |
| DA | 2024-01-31 | 2024-01-10 | CRL | Girshick Birgit | COO, Corp. Executive VP | M - OptEx | $144.67 | +5,916 | 50.4K | +13% | +$855.9K |
| DA | 2024-01-31 | 2024-01-10 | CRL | Girshick Birgit | COO, Corp. Executive VP | M - OptEx | $0.00 | -5,916 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-10 | F | D | 4,617 | $213.14 | 45,748 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-10 | M | A | 5,916 | $144.67 | 50,365 | D | — | — | |
| 3 | Derivative | Stock Options (Right to Buy) | 2024-01-10 | M | D | 5,916 | $0.00 | 0 | D | $144.67 · 2020-02-22 to 2024-02-22 | 5,916 Common Stock | (F1) The transaction was executed as a net exercise, in which no shares were purchased or sold in the open market. |